BIOMAT Database Logo BIOMAT Database Logo

Effect of anticoagulant therapy on antithrombin III levels. 1982

M S Sirridge, and R Shannon, and W M Hardin

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses

Related Publications

M S Sirridge, and R Shannon, and W M Hardin
The anticoagulant effect of antithrombin III on hyperacute xenograft rejection.
April 1996, Transplantation proceedings,
M S Sirridge, and R Shannon, and W M Hardin
L-asparaginase effect on antithrombin-III levels.
January 1979, Medical and pediatric oncology,
M S Sirridge, and R Shannon, and W M Hardin
[Effect of antithrombin III concentrate infusion therapy on congenital antithrombin III deficiency].
January 1984, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M S Sirridge, and R Shannon, and W M Hardin
Effect of long-term anticoagulant therapy on antithrombin activity.
January 1965, Therapia Hungarica (English edition),
M S Sirridge, and R Shannon, and W M Hardin
Antithrombin III levels during heparin therapy.
January 1981, Thrombosis research,
M S Sirridge, and R Shannon, and W M Hardin
[Antithrombin III control in patients with long-term anticoagulant therapy].
January 1991, Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichts-Chirurgie,
M S Sirridge, and R Shannon, and W M Hardin
Changes in antithrombin 3 levels following cessation of anticoagulant therapy.
April 1973, Acta medica Scandinavica,
M S Sirridge, and R Shannon, and W M Hardin
Effect of various estrogen treatment schedules on antithrombin III levels.
July 1976, Research communications in chemical pathology and pharmacology,
M S Sirridge, and R Shannon, and W M Hardin
The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
September 2009, Anesthesia and analgesia,
M S Sirridge, and R Shannon, and W M Hardin
The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III.
February 1990, Thrombosis research,
Copied contents to your clipboard!